Skip to main content
Caplight Logo







Company Database

Top Healthcare Companies

The most valuable private healthcare and life sciences companies, ranked by their latest post-money valuation.

25 companies · Updated November 22, 2026

Top Healthcare Companies
CompanySectorStageValuationLatest FundingTotal FundingHeadcountMomentumLocationWebsiteBusiness ModelCustomer Profile
Consumer & CommerceEquity Financing$38B$1.27B (Dec 2018)$14.05B1,179
Washington D.C.www.juullabs.comB2CUsage-Based SaaS, Hardware Sales
Healthcare & Life SciencesSeries G$25B$555M (Oct 2026)$3.59B1,489
Waltham, Massachusettswww.devoted.comB2CGovernment Contracts
Healthcare & Life SciencesGrowth Equity$20B$200M (Jul 2026)$935M132
Miami, Floridawww.openevidence.comB2BData as a Service, Subscription SaaS
Healthcare & Life SciencesSeries C$17.5B$5B (May 2026)$7.7B435
Londonwww.isomorphiclabs.comB2BServices & Consulting, Revenue Share
Healthcare & Life SciencesDebt$17B$500M (Feb 2022)$49.5M9,066
Boston, Massachusettswww.athenahealth.comB2BRevenue Share, Subscription SaaS, Services & Consulting
Healthcare & Life SciencesVC Round$12.44B$120M (Aug 2018)$658M21
San Diego, Californiawww.biosplice.com/default.aspxB2BServices & Consulting
Consumer & CommerceSeries E Extension$11.06B$62.67M (Mar 2026)$1.3B1,325
San Francisco, Californiawww.ouraring.comB2CHardware Sales, Hardware + Subscription, Subscription SaaS, Government Contracts
Healthcare & Life SciencesSeries E$11B$900M (Oct 2025)$1.24B-
San Francisco, Californiawww.oura-app.comB2CHardware + Subscription
Healthcare & Life SciencesSeries B$10.5B$2B (Jun 2026)$2.55B511
Cambridge, Massachusettswww.lila.aiB2BServices & Consulting, Usage-Based SaaS
Healthcare & Life SciencesSeries C Extension$10.32B$120M (Sep 2025)$545M215
Austin, Texaswww.colossal.comB2BServices & Consulting, Government Contracts, Data as a Service
Consumer & CommerceSeries G$10.1B$575M (Mar 2026)$979.39M1,084
Boston, Massachusettswww.whoop.comB2CHardware + Subscription, Subscription SaaS, Hardware Sales
Healthcare & Life SciencesSeries E$9.6B$650M (May 2025)$1.26B465
Fremont, Californiawww.neuralink.comB2CHardware Sales, Services & Consulting
Healthcare & Life SciencesSecondary$8.5B$260M (Oct 2022)$57.1M9,820
Ahmedabadwww.intaspharma.comB2BHardware Sales, Services & Consulting
Healthcare & Life SciencesM&A$7B$7B (Nov 2025)$505M108
New York City, New Yorkwww.metsera.comB2BGovernment Contracts, Hardware Sales, Revenue Share
Frontier & Industrial TechSeries C$7B$1.4B (Jun 2026)$2.81B559
Metzingenwww.neura-robotics.comB2BHardware Sales, Subscription SaaS, Usage-Based SaaS, Marketplace Commission
Healthcare & Life SciencesSecondary$7B$60M (Jan 2026)$178.19M-
San Diego, Californiawww.valasciences.comB2BHardware Sales, Services & Consulting, Subscription SaaS
Healthcare & Life SciencesVC Round$7B$70M (May 2026)$1B1,554
Mountain View, Californiawww.commure.comB2BSubscription SaaS, Services & Consulting
Healthcare & Life SciencesSeries D Extension$7B$150M (Feb 2022)$1.03B711
New York City, New Yorkwww.ro.coB2CUsage-Based SaaS, Subscription SaaS
Healthcare & Life SciencesM&A$7B(Jun 2021)$80.5M7,402
Phoenix, Arizonawww.datavant.comB2BSubscription SaaS, Usage-Based SaaS, Services & Consulting
Healthcare & Life SciencesSeries C$7B$700M (Jul 2026)$1.03B639
Stockholmwww.nekohealth.comB2CHardware + Subscription, Usage-Based SaaS
Healthcare & Life SciencesSeries G$6.7B$66.88M (Dec 2022)$1.82B-
Hangzhouwww.guahao.comB2B2CSubscription SaaS, Marketplace Commission, Government Contracts, Hardware Sales
Healthcare & Life SciencesPrivate Equity$6.6B$200M (Jul 2025)$453M7,246
Vapiwww.merillife.comB2BHardware Sales
Healthcare & Life SciencesIPO$6.5B$805.9M (Feb 2021)-11
Beijingwww.safeglp.comB2BServices & Consulting, Data as a Service, Hardware Sales
Healthcare & Life SciencesVC Round$6.33B$3B (Jan 2022)-439
Redwood City, Californiawww.altoslabs.comB2BServices & Consulting
FinTechSeries G$6.3B$550M (Jun 2026)$1.3B871
Pariswww.alan.comB2B2CSubscription SaaS

Companies are classified into this sector based on Caplight sector and vertical tagging, then ranked by most recent post-money valuation.